Literatur
- 01
Algan O, Fosmire H, Hynynen K, Dalkin B, Cui H, Drach G, Stea B, Cassady J R.
External beam radiotherapy and hyperthermia in the treatment of patients with
locally advanced prostate carcinoma.
Cancer.
2000;
89
(2)
399-403
- 02
Bogovic J, Douwes F, Muravjov G, Istomin J.
Posttreatment histology and microcirculation status of osteogenic sarcoma after
a neoadjuvant chemo- and radiotherapy in combination with local electromagnetic
hyperthermia.
Onkologie.
2001;
24
(1)
55-8
- 03
Douwes F R, Migeod F H, Bogovic J, Grote C.
Whole body hyperthermia in combination with platinum containing compounds in
advanced ovarian cance.
Int J Clin Oncology.
2004;
985-91
- 04
Gaworek J, Mayer T.
Systemische Ganzkörperhyperthermie in der Onkologie: Tödliche Hitze für Tumorzelle.
Pflegepraxis.
2003;
1
15-18
- 05
Hamazoe R, Murakami A, Hirooka Y, Maeta M, Kaibara N.
A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial
chemotherapy using cisplatinum and 5-fluorouracil.
J Surg Oncol.
1991;
48
(2)
127-32
- 06
Issels R D.
Hyperthermia combined with chemotherapy - Biological rationale, clinical application,
and treatment results.
Onkologie.
1999;
22
374-381
- 07
Issels R D, Abdel-Rahman S, Wendtner C. et al .
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally
advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of
adults: long-term results of a phase II study.
Eur J Cancer.
2001;
37
(13)
1599-608
- 08
Kakehi M, Ueda K, Mukojima T. et al .
Multi-institutional clinical studies on hyperthermia combined with radiotherapy
or chemotherapy in advanced cancer of deep-seated organs.
Int J Hyperthermia.
1990;
6
(4)
719-40
- 09
Katschinski D M, Wiedemann G J, Mentzel M, Mulkerin D L, Touhidi R, Robins H I.
Optimization of chemotherapy administration for clinical 41.8 degrees C whole
body hyperthermia.
Cancer Lett.
1997;
115
(2)
195-9
- 10
Katschinski D M, Wiedemann G J, Longo W, d'Oleire F R, Spriggs D, Robins H I.
Whole body hyperthermia cytokine induction: a review, and unifying hypothesis
for myeloprotection in the setting of cytotoxic therapy.
Cytokine Growth Factor Rev.
1999;
10
(2)
93-7
- 11
Konrad R N, Reichel M.
Effekte der extremen Ganzkörperhyperthermie.
Naturheilpraxis.
1998;
935-940
- 12
Li Q, Bostick-Bruton F, Reed E.
Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced
ERCC-1 mRNA expression in a human ovarian carcinoma cell line.
Anticancer Res.
1998;
18
(4A)
2283-7
- 13
Multhoff G.
Heat shock protein 72 (HSP72), a hyperthermia-inducible immunogenic determinanton
leukemic K562 and Ewing's sarcoma cells.
Int J Hyperthermia.
1997;
13
(1)
39-48
- 14
Overgaard J, Gonzalez Gonzalez D, Hulshof M C. et al .
Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or
metastatic malignant melanoma. European Society for Hyperthermic Oncology.
Lancet.
1995;
345
(8949)
540-3
- 15
Raaphorst G P, Doja S, Davis L, Stewart D, Ng C E.
A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma
and glioma cell lines sensitive and resistant to cisplatin treatment.
Cancer Chemother Pharmacol.
1996;
37
(6)
574-80
- 16
Rietbroek R C, Schilthuis M S, Bakker P J. et al .
Phase II trial of weekly locoregional hyperthermia and cisplatin in patients
with a previously irradiated recurrent carcinoma of the uterine cervix.
Cancer.
1997;
79
(5)
935-43
- 17
Rau B, Wust P, Gellermann J. et al .
Phase-II-Studie zur präoperativen Radio-, Chemo-, Thermotherapie beim lokal
fortgeschrittenen Rektum-Karzinom.
Strahlenther Onkol.
1998;
174
(11)
556-65
- 18
Reichel M, Douwes F R, Scheeren T, Douwes O, Konrad R N.
Tiefe intravenöse Analgosedierung zur extremen Ganzkörperhyperthermie in Kombination
mit Chemotherapie.
Forschung und Praxis.
2004;
3
4-8
- 19
Rietbroek R C, Bakker P J, Schilthuis M S. et al .
Feasibility, toxicity, and preliminary results of weekly loco-regional hyperthermia
and cisplatin in patients with previously irradiated recurrent cervical carcinoma
or locally advanced bladder cancer.
Int J Radiat Oncol Biol Phys.
1996;
34
(4)
887-93
- 20
Robins H I, Dennis W H, Neville A J. et al .
A nontoxic system for 41.8 degrees C whole-body hyperthermia: results of a Phase
I study using a radiant heat device.
Cancer Res.
1985;
45
(8)
3937-44
- 21
Robins H I, Cohen J D, Schmitt C L. et al .
Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia
in cancer patients.
J Clin Oncol.
1993;
11
(9)
1787-94
- 22
Robins H I, Rushing D, Kutz M. et al .
Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia
in cancer patients.
J Clin Oncol.
1997;
15
(1)
158-64
- 23
Sakaguchi Y, Stephens L C, Makino M. et al .
Apoptosis in tumors and normal tissues induced by whole body hyperthermia in
rats.
Cancer Res.
1995;
55
(22)
5459-64
- 24
Schaefer C, Mayer W K, Kruger W, Vaupel P.
Microregional distributions of glucose, lactate, ATP and tissue pH in experimental
tumours upon local hyperthermia and/or hyperglycaemia.
J Cancer Res Clin Oncol.
1993;
119
(10)
599-608
- 25
Sneed P K, Gutin P H, Stauffer P R. et al .
Thermoradiotherapy of recurrent malignant brain tumors.
Int J Radiat Oncol Biol Phys.
1992;
23
(4)
853-61
- 26
Sneed P K, Stauffer P R, McDermott M W. et al .
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy
boost +/- hyperthermia for glioblastoma multiforme.
Int J Radiat Oncol Biol Phys.
1998;
40
(2)
287-95
- 27
Valdagni R, Amichetti M.
eport of long-term follow-up in a randomized trial comparing radiation therapy
and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV
head and neck patients.
Int J Radiat Oncol Biol Phys.
1994;
28
(1)
163-9
- 28
Zee J van der, Rhoon G C van, Wike-Hooley J L, Faithfull N S, Reinhold H S.
Whole-body hyperthermia in cancer therapy: a report of a phase I-II study.
Eur J Cancer Clin Oncol.
1983;
19
(9)
1189-200
- 29
Zee J van der, Gonzalez Gonzalez D, Rhoon G C van, Dijk J D van, Putten W L van,
Hart A A.
Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally
advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch
Deep Hyperthermia Group.
Lancet.
2000;
355
(9210)
1119-25
- 30
Vernon C C, Hand J W, Field S B. et al .
Radiotherapy with or without hyperthermia in the treatment of superficial localized
breast cancer: results from five randomized controlled trials. International
Collaborative Hyperthermia Group.
Int J Radiat Oncol Biol Phys.
1996;
35
(4)
731-44
- 31
Wessalowski R, Kruck H, Pape H, Kahn T, Willers R, Gobel U.
Hyperthermia for the treatment of patients with malignant germ cell tumors:
a phase I/II study in ten children and adolescents with recurrent or refractory
tumors.
Cancer.
1998;
82
(4)
793-800
- 32
Westermann A M, Grosen E A, Katschinski D M. et al .
A pilot study of whole body hyperthermia and carboplatin in platinum-resistant
ovarian cancer.
Eur J Cancer.
2001;
37
(9)
1111-7
- 33
Wiedemann G J, d'Oleire F, Knop E. et al .
Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia
in patients with refractory sarcoma and malignant teratoma.
Cancer Res.
1994;
54
(20)
5346-50
- 34
Wiedemann G J, Robins H I, Gutsche S. et al .
Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole
body hyperthermia in patients with refractory sarcoma.
Eur J Cancer.
1996;
32A
(5)
888-92
Korrespondenzadresse
Dr. med. Friedrich Douwes
Ärztl. Direktor der Klinik St. Georg
Präsident der Deutschen Gesellschaft für Onkologie
Rosenheimerstr. 6-8
83043 Bad Aibling
eMail: drdouwes1@aol.de
